Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat domain 70 is a scaffold protein composed of six WD40 repeat domains that assemble into multiprotein complexes critical for DNA double-strand break repair. It functions as a subunit of the CRL4 complex and interacts with RNF20/40 E3 ligases to mediate monoubiquitylation of histone H2B, thereby enabling recruitment and transcription of major homology-directed repair genes such as BRCA1, BRCA2, and RAD51[2][1]. Loss or mutation of WDR70 impairs DNA repair, leading to genomic instability and increased susceptibility to carcinogenesis, especially in colorectal cancer[2]. There is growing interest in targeting WDR70 for therapeutic intervention in cancer, yet direct, clinically-approved drugs are not currently available[3].
Drug targeting would likely act by: - Modulating protein-protein interactions within DNA repair or chromatin complexes - Affecting E3 ligase-mediated histone ubiquitylation - Altering transcriptional regulation of key DNA repair genes (BRCA1, BRCA2, RAD51)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat domain 70 (WDR70).